We are live on
!
Find out more
DM
Deerfield Management Portfolio holdings
AUM
$8.48B
1-Year Est. Return
99.04%
This Fund
S&P 500
This Quarter
Est. Return
-10.7%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$2.35B
AUM Growth
-$119M
(-4.8%)
Cap. Flow
-$74.1M
Cap. Flow
% of AUM
-3.15%
Top 10 Holdings %
Top 10 Hldgs %
36.4%
Holding
125
New
15
Increased
30
Reduced
16
Closed
20
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
PTLA
Portola Pharmaceuticals, Inc.
PTLA
|
+$76.3M |
| 2 |
AVXS
AveXis, Inc. Common Stock
AVXS
|
+$48.9M |
| 3 |
Editas Medicine
EDIT
|
+$44.9M |
| 4 |
Viatris
VTRS
|
+$37.5M |
| 5 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$36M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
DYAX
DYAX CORPORATION
DYAX
|
+$84.3M |
| 2 |
Teva Pharmaceuticals
TEVA
|
+$53.5M |
| 3 |
Charles River Laboratories
CRL
|
+$30.3M |
| 4 |
GHDX
Genomic Health, Inc.
GHDX
|
+$28.5M |
| 5 |
Pacira BioSciences
PCRX
|
+$28.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 69.81% |
| 2 | Financials | 4.2% |
| 3 | Technology | 0.53% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
101
Teva Pharmaceuticals
TEVA
$36.8B
| – | – |
-815,000
| Closed | -$53.5M |
|
|
TRIB
102
Trinity Biotech
TRIB
$6.38M
| – | – |
-49,200
| Closed | -$2.89M |
|
|
ARAV
103
DELISTED
Aravive, Inc. Common Stock
ARAV
| – | – |
-81,751
| Closed | -$6.08M |
|
|
CSII
104
DELISTED
Cardiovascular Systems, Inc.
CSII
| – | – |
-1,035,000
| Closed | -$15.6M |
|
|
ATRS
105
DELISTED
Antares Pharma, Inc.
ATRS
| – | – |
-3,983,440
| Closed | -$4.82M |
|
|
GEN
106
DELISTED
Genesis Healthcare, Inc.
GEN
| – | – |
-963,564
| Closed | -$3.34M |
|
|
IMMU
107
DELISTED
Immunomedics Inc
IMMU
| – | – |
-1,073,640
| Closed | -$3.3M |
|
|
ACHN
108
DELISTED
Achillion Pharmaceuticals
ACHN
| – | – |
-1,667,000
| Closed | -$18M |
|
|
GHDX
109
DELISTED
Genomic Health, Inc.
GHDX
| – | – |
-809,432
| Closed | -$28.5M |
|
|
POZN
110
DELISTED
POZEN INC
POZN
| – | – |
-44,583
| Closed | -$305K |
|
|
DYAX
111
DELISTED
DYAX CORPORATION
DYAX
| – | – |
-2,242,073
| Closed | -$84.3M |
|
|
CTIC
112
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
| – | – |
-223,683
| Closed | -$2.75M |
|
Similar funds
FT
GRQ
PCM
VA
QC
IC
NW
AAF
Deerfield Management's Q1 2016 Portfolio in Review
As of Q1 2016, Deerfield Management held 125 positions worth $2.35B, down 4.8% from $2.47B the previous quarter. Its ten largest holdings account for 36% of the portfolio.
Deerfield Management withdrew a net $74.1M in Q1 2016, closing 20 positions and reducing 16 holdings. Its most notable exit was DYAX CORPORATION, an estimated $84.3M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 70% of assets, up from 68% a quarter earlier, followed by Financials and Technology.
Against the trend, Deerfield Management opened a new position in AveXis, Inc. Common Stock worth $60.9M.
- Deerfield Management's largest Q1 2016 buy was AveXis, Inc. Common Stock: 2,236,701 shares worth $60.9M.
- Deerfield Management added most to Portola Pharmaceuticals, Inc. in Q1 2016, an estimated $76.3M increase.
- Deerfield Management's biggest Q1 2016 reduction was Adeptus Health Inc, cutting an estimated $18.2M.
- Deerfield Management fully exited DYAX CORPORATION in Q1 2016, selling an estimated $84.3M.
- Deerfield Management's ten largest holdings make up 36% of its $2.35B portfolio in Q1 2016.
- Deerfield Management opened 15 new positions and closed 20 in Q1 2016.
- Deerfield Management's portfolio value fell 4.8% quarter-over-quarter to $2.35B.
Based on Deerfield Management's 13F filing for Q1 2016, filed 16 May 2016.